c-MET anticorps (Tyr1349)

N° du produit ABIN197479

Détail du produit anti-c-MET anticorps

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Épitope: Tyr1349

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp c-MET est non-conjugé

Application: Western Blotting (WB)

Specificité: Met antibody detects endogenous levels of total Met protein.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogène: The antiserum was produced against synthesized non-phosphopeptide derived from human Met around the phosphorylation site of tyrosine 1349 (E-H-YP-V-H).

Information d'application

Indications d'application: Western Blot: 1: 500approx. 1: 1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: PBS (without Mg2+ and Ca2+), pH 7.4 containing 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Détails sur c-MET

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: HGF Receptor (MET Produits)

Synonymes: anticorps AUTS9, anticorps HGFR, anticorps RCCP2, anticorps c-Met, anticorps AI838057, anticorps HGF, anticorps Par4, anticorps Hgfr, anticorps c-met, anticorps MET, anticorps C-MET, anticorps met, anticorps met-A, anticorps MET proto-oncogene, receptor tyrosine kinase, anticorps met proto-oncogene, anticorps MET proto-oncogene, receptor tyrosine kinase L homeolog, anticorps MET, anticorps Met, anticorps met.L

Sujet: C-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells. HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptor's cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met

ID gène: 4233

NCBI Accession: NP_000236

UniProt: P08581

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor